Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: Application for allogeneic transplantation

Hiroki Torikai, Yoshiki Akatsuka, Yasushi Yatabe, Yasuo Morishima, Yoshihisa Kodera, Kiyotaka Kuzushima, Toshitada Takahashi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

It has been shown that allogeneic hematopoietic stem cell transplantation (HSCT) can be one of the therapeutic options for patients with metastatic solid tumors, such as renal cancer. However, the development of relatively severe GVHD seems to be necessary to achieve tumor regression in the current setting. Thus, it is crucial to identify minor histocompatibility antigens (mHags) only expressed in tumor cells but not GVHD target organs. In this study, we examined whether three mHags: ACC-1 and ACC-2 encoded by BCL2A1, and HA-1 encoded by HMHA1, could serve as such targets for melanoma. Real-time PCR and immunohistochemical analysis revealed that the expression of both BCL2A1and HMHA1 in melanoma cell lines and primary melanoma cells was comparable to that of hematopoietic cells. Indeed, melanoma cell lines were efficiently lysed by cytotoxic T lymphocytes specific for ACC-1, ACC-2, and HA-1. Our data suggest that targeting mHags encoded not only by HMHA1, whose aberrant expression in solid tumors has been reported, but also BCL2A1 may bring about beneficial selective graft-versus-tumor effects in a population of melanoma patients for whom these mHags are applicable.

Original languageEnglish
Pages (from-to)467-473
Number of pages7
JournalInternational Journal of Hematology
Volume87
Issue number5
DOIs
Publication statusPublished - 01-06-2008
Externally publishedYes

Fingerprint

Minor Histocompatibility Antigens
Homologous Transplantation
Melanoma
Neoplasms
Cell Line
Kidney Neoplasms
Hematopoietic Stem Cell Transplantation
Cytotoxic T-Lymphocytes
Real-Time Polymerase Chain Reaction
Transplants
Population

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Torikai, Hiroki ; Akatsuka, Yoshiki ; Yatabe, Yasushi ; Morishima, Yasuo ; Kodera, Yoshihisa ; Kuzushima, Kiyotaka ; Takahashi, Toshitada. / Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells : Application for allogeneic transplantation. In: International Journal of Hematology. 2008 ; Vol. 87, No. 5. pp. 467-473.
@article{eaf0e9b4293849a7b87200aec3184b9a,
title = "Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: Application for allogeneic transplantation",
abstract = "It has been shown that allogeneic hematopoietic stem cell transplantation (HSCT) can be one of the therapeutic options for patients with metastatic solid tumors, such as renal cancer. However, the development of relatively severe GVHD seems to be necessary to achieve tumor regression in the current setting. Thus, it is crucial to identify minor histocompatibility antigens (mHags) only expressed in tumor cells but not GVHD target organs. In this study, we examined whether three mHags: ACC-1 and ACC-2 encoded by BCL2A1, and HA-1 encoded by HMHA1, could serve as such targets for melanoma. Real-time PCR and immunohistochemical analysis revealed that the expression of both BCL2A1and HMHA1 in melanoma cell lines and primary melanoma cells was comparable to that of hematopoietic cells. Indeed, melanoma cell lines were efficiently lysed by cytotoxic T lymphocytes specific for ACC-1, ACC-2, and HA-1. Our data suggest that targeting mHags encoded not only by HMHA1, whose aberrant expression in solid tumors has been reported, but also BCL2A1 may bring about beneficial selective graft-versus-tumor effects in a population of melanoma patients for whom these mHags are applicable.",
author = "Hiroki Torikai and Yoshiki Akatsuka and Yasushi Yatabe and Yasuo Morishima and Yoshihisa Kodera and Kiyotaka Kuzushima and Toshitada Takahashi",
year = "2008",
month = "6",
day = "1",
doi = "10.1007/s12185-008-0076-5",
language = "English",
volume = "87",
pages = "467--473",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells : Application for allogeneic transplantation. / Torikai, Hiroki; Akatsuka, Yoshiki; Yatabe, Yasushi; Morishima, Yasuo; Kodera, Yoshihisa; Kuzushima, Kiyotaka; Takahashi, Toshitada.

In: International Journal of Hematology, Vol. 87, No. 5, 01.06.2008, p. 467-473.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells

T2 - Application for allogeneic transplantation

AU - Torikai, Hiroki

AU - Akatsuka, Yoshiki

AU - Yatabe, Yasushi

AU - Morishima, Yasuo

AU - Kodera, Yoshihisa

AU - Kuzushima, Kiyotaka

AU - Takahashi, Toshitada

PY - 2008/6/1

Y1 - 2008/6/1

N2 - It has been shown that allogeneic hematopoietic stem cell transplantation (HSCT) can be one of the therapeutic options for patients with metastatic solid tumors, such as renal cancer. However, the development of relatively severe GVHD seems to be necessary to achieve tumor regression in the current setting. Thus, it is crucial to identify minor histocompatibility antigens (mHags) only expressed in tumor cells but not GVHD target organs. In this study, we examined whether three mHags: ACC-1 and ACC-2 encoded by BCL2A1, and HA-1 encoded by HMHA1, could serve as such targets for melanoma. Real-time PCR and immunohistochemical analysis revealed that the expression of both BCL2A1and HMHA1 in melanoma cell lines and primary melanoma cells was comparable to that of hematopoietic cells. Indeed, melanoma cell lines were efficiently lysed by cytotoxic T lymphocytes specific for ACC-1, ACC-2, and HA-1. Our data suggest that targeting mHags encoded not only by HMHA1, whose aberrant expression in solid tumors has been reported, but also BCL2A1 may bring about beneficial selective graft-versus-tumor effects in a population of melanoma patients for whom these mHags are applicable.

AB - It has been shown that allogeneic hematopoietic stem cell transplantation (HSCT) can be one of the therapeutic options for patients with metastatic solid tumors, such as renal cancer. However, the development of relatively severe GVHD seems to be necessary to achieve tumor regression in the current setting. Thus, it is crucial to identify minor histocompatibility antigens (mHags) only expressed in tumor cells but not GVHD target organs. In this study, we examined whether three mHags: ACC-1 and ACC-2 encoded by BCL2A1, and HA-1 encoded by HMHA1, could serve as such targets for melanoma. Real-time PCR and immunohistochemical analysis revealed that the expression of both BCL2A1and HMHA1 in melanoma cell lines and primary melanoma cells was comparable to that of hematopoietic cells. Indeed, melanoma cell lines were efficiently lysed by cytotoxic T lymphocytes specific for ACC-1, ACC-2, and HA-1. Our data suggest that targeting mHags encoded not only by HMHA1, whose aberrant expression in solid tumors has been reported, but also BCL2A1 may bring about beneficial selective graft-versus-tumor effects in a population of melanoma patients for whom these mHags are applicable.

UR - http://www.scopus.com/inward/record.url?scp=46149084174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46149084174&partnerID=8YFLogxK

U2 - 10.1007/s12185-008-0076-5

DO - 10.1007/s12185-008-0076-5

M3 - Article

C2 - 18414982

AN - SCOPUS:46149084174

VL - 87

SP - 467

EP - 473

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -